Search Results

ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation, following the Orphan Drug Designation for ABM-1310 to treat malignant gliomas including GBM received in July.

ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignant brain tumors in China. This is the second clinical study of ABM-1310 in China.

ABM Therapeutics today announced that the first patient was successfully dosed with ABM-168 in the United States.

ABM Therapeutics (ABM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed by the company, for the treatment of patients with glioblastoma (GBM) bearing BRAF V600 mutation.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, is thrilled to announce a US exclusive distribution partnership with Mercury Medical for non-government acute care facilities.

Arcade Therapeutics and University of Texas Austin’s Institute for Mental Health Research jointly announced the closing of a $3.8M grant from the National Institute for Mental Health (NIMH) to support clinical investigation and validation of ABM-02 as a game-based treatment for Major Depressive Disorder (MDD).

ABM Therapeutics announced that its IND application for ABM-1310, a new-generation BRAF inhibitor, has been approved by the National Medical Products Administration to conduct Phase 1 clinical trials in patients of advanced solid tumors with BRAF mutation in China.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced the U.S. Food and Drug Administration 510 clearance of the BiWaze® Clear System.